Sergej Boljević, an expert in the field of pathophysiology and immunology, professor at Moscow State University "IM Sechenov", at a meeting with the Director of the Health Insurance Fund (FZO) Vuk Kadić, presented the work of the scientific team of which he is a member, on the development of an innovative vaccine that could be used for two types of cancer - melanoma and non-small cell lung cancer.
The Health Insurance Fund emphasizes in a statement that these are vaccines that are based on the latest technologies and have shown exceptional results in preclinical trials, with an efficacy rate of up to 95 percent.
A personalized mRNA vaccine, which, as they explained, is based on immunotherapy, has already been developed and is awaiting approval from the relevant health institutions in Russia to begin clinical use.
Kadić pointed out that Montenegro, according to current regulations, does not have the possibility to participate in experimental projects, but that such interest will exist from the moment vaccines are officially accepted as a therapy in the fight against cancer. He suggested that a delegation from Russia come to Montenegro to present their work on the project.
"It was emphasized that there is a possibility that the aforementioned technology will be transferred to Serbia and that this vaccine will be made there, which, according to Director Kadić, will be a mitigating circumstance for Montenegro to send patients to Serbia where they could receive this innovative therapy," the statement reads.
Kadić said that the Health Insurance Fund, when the conditions are right, will find funds to participate in the project "which aims to improve the health condition of patients with the most serious illnesses."
The meeting was also attended by the assistant directors of the Health Insurance Fund, Radovan Nikolić and Zdravko Vuksanović.
Bonus video:
